Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Strides Pharma...

    Strides Pharma suspends sale of Ranitidine tab in US

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-27T09:56:18+05:30  |  Updated On 16 Aug 2021 2:08 PM IST
    New Delhi: Strides Pharma Science on Friday suspended the sale of Ranitidine tablets after it received an information request from the US health regulator to provide test data related to impurities in the drug. Ranitidine tablets are used to treat peptic ulcers of the stomach and intestines.

    Data related to N-nitrosodimethylamine impurities is to be provided to the agency in 30 days.

    Also read:-Dr Reddys suspends worldwide supply of Ranitidine over cancer fears until USFDA probe over


    "While the company conducts the relevant tests mandated by the the United States Food and Drug Administration (USFDA), it has suspended sales of Ranitidine tablets in the US market until such time it has clarity of next steps as would be indicated by the USFDA," Strides Pharma Science said in a BSE filing.
    The company said it predominantly sells Ranitidine tablets in the US markets, and its front end sales globally for the product stood at USD 9 million in the first half of the current financial year.

    Ranitidine tablets is amongst the top 5 products sold by the company in the USA.

    Also read:-CDSCO warns against Cancer Causing Impurities in anti-acidity drug Ranitidine, writes to state drug controllers

    Strides Pharma Science said in spite of this temporary suspension of the Ranitidine supplies, the company retains its growth outlook for the current financial year for the US markets.

    agencydrugpeptic ulcersranitidineStrides PharmaUnited StatesUSAUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok